Joseph Riad, MD
Colon & Rectal Surgery · New York, NYNPI 1720493729
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,714 of the $4,384 with a category attached, or 61.9%. Intuitive Surgical accounts for 67.8% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $3,433 and has fallen 98.9% since, to $39 in 2024.
Across 25 payments — averaging $175.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Medtronic$761
- Stryker$414
- Boston Scientific$132
- Integra Lifesciences Corporation$39
- Lilly USA, LLC$28
- plus $38 from 2 others
What the payments were for
- Travel & lodging$2,71462%
- Food & beverage$65715%
- Education$1,00023%
- Gifts$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $2,970 |
| Medtronic | 10 | $761 |
| Stryker | 2 | $414 |
| Boston Scientific | 1 | $132 |
| Integra Lifesciences Corporation | 1 | $39 |
| Lilly USA, LLC | 1 | $28 |
| Smith+Nephew | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,919
- DAVINCI XI$1,000
- INTERSTIM$556
- SPY-PHI SYSTEM$399
- RESOLUTION CLIP$132
How this compares
$4,384 in reported general payments places this provider in the 70th percentile of 177 colon & rectal surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocortisone | 25 | $316 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 23 | $296 |
| Procto-Med HcHydrocortisone | 18 | $215 |
| Neomycin Sulfate | 15 | $65 |
| Metronidazole | 14 | $10 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in New York
- Sanghyun KimNew York$154K
- Mehraneh JafariNew York$50K
- Jeffrey MilsomNew York$42K
- David SchwartzbergNew York$26K
- Richard WhelanNew York$23K
- Alessandro FicheraNew York$20K
- Juliet RayNew York$17K
- Cary AaronsNew York$16K
- Debbie BakesNew York$15K
- Parul ShuklaNew York$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.